ClinicalTrials.gg
CompletedNCT01289080Updated Oct 29, 2015Results posted

Trial Evaluating OPC-34712 in Subjects With Normal Renal Function and Renally Impaired Subjects

A Phase 1 interventional study of OPC-34712 in Schizophrenia and Psychiatric Disorders, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-10-29.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
19
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 28 studies testing brexpiprazole in Schizophrenia — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Schizophrenia.

Enrollment
25th of 28
19 · median 155
Started
2011
with 6 others
Phase 1
8 of 28
1 open now
Registered
3rd of 28
by date
Lead sponsor
19 of 28
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 28 studies testing brexpiprazole in Schizophrenia, this one is the 25th largest by enrollment, is one of 7 that started in 2011, is one of 8 in phase 1, and was the 3rd registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 496 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

1 of the 28 studies testing brexpiprazole in Schizophrenia is open now. Recruiting first, the newest first:

About brexpiprazole

brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 334 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 259 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing brexpiprazole in Schizophrenia, or all of them as a file.
02

Study summary

This trial is an open-label, multi-center, parallel-arm, single-dose trial in 2 groups: 1 group of subjects with normal renal function and 1 group of severely renally impaired subjects.

03

Conditions studied

  • Schizophrenia
  • Psychiatric Disorders

Keywords

  • Schizophrenia
  • psychiatric disorders
  • renal failure
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Male or female (non-) subjects ≥ 18 years of age.
  • Ability to provide written prior to initiation of any trial-related procedures, and ability, in the opinion of the principal investigator, to comply with all the requirements of the trial.
  • Male and female subjects who are surgically sterile; female subjects who have been for at least 12 consecutive months (confirmed by follicle stimulating hormone sample at Screening); or male subjects who agree to remain abstinent or to practice double-barrier forms of and refrain from sperm donation from trial Screening through 90 days from the last dose of the medicinal product.
  • Body weight within ± 35% of ideal body weight as defined in the 1983 Metropolitan Height and Weight Tables (see Appendix 4, Appendix 5, and Appendix 6). Minimum body weight no less than 50 kg.

Inclusion Criteria for Subjects with Normal Renal Function

  • Subjects who are in good health as determined by a medical history, physical examination, serum chemistry, hematology, urinalysis, and C tests, and (HIV) testing.
  • > 80 mL/min indicating normal renal function.

Inclusion Criteria for Renally Impaired Subjects

  • Renally impaired subjects may be taking medications which, in the opinion of the clinical investigator and sponsor, are believed to be therapeutic for the subjects (but do not affect OPC-34712 absorption, distribution, metabolism, or elimination). Inhibitors and inducers of and inhibitors of CYP2D6 are not allowed.
  • Creatinine clearance \< 30 mL/min indicating severe renal impairment.
  • Subjects with renal impairment should have relatively stable renal function as determined by creatinine clearance and otherwise be in generally good health.

Exclusion Criteria:

abnormality in past medical history, or at the screening physical examination, that in the investigator's or sponsor's opinion may place the subject at risk or interfere with outcome variables including absorption, distribution, metabolism, and excretion of drug.

  • Any surgical or medical condition (active or chronic) that may interfere with drug absorption, distribution, metabolism, or excretion, or any other condition that may place the subject at risk.
  • History of drug and/or alcohol abuse within 2 years prior to Screening.
  • A positive urine alcohol test and/or urine drug screen for substance of abuse at Screening or upon check-in to the trial site.
  • The donation of blood or plasma within 30 days prior to dosing.
  • Any history of significant bleeding or hemorrhagic tendencies.
  • History of or current hepatitis or carriers of hepatitis B surface antigen (HBsAg) and/or antibodies (anti-HCV).
  • History of acquired immunodeficiency syndrome or determined human immunodeficiency virus (HIV) positive at Screening.
  • Use of an investigational drug or product, or participation in a drug trial within 30 days prior to dosing.
  • Previous exposure to OPC-34712.
  • History of clinically significant drug allergies or sensitivities.
  • Subjects who are pregnant or breastfeeding. A negative serum pregnancy test must be confirmed prior to administration of trial medication for all female subjects.
  • Subjects who have a supine pulse rate, after resting for ≥ 3 minutes, outside the range of 40 to 90 bpm. The sponsor may allow exceptions if they are not deemed clinically significant.

Exclusion Criteria for Healthy Subjects

  • Clinically significant abnormal findings in the serum chemistry, hematology, or urinalysis results obtained at Screening or Day -1.
  • Use of prescription, over-the-counter, herbal medication or vitamin supplements within 14 days prior to dosing and antibiotics within 30 days prior to dosing. The sponsor may allow exceptions only if the medication's administration is deemed unlikely to impact the pharmacokinetic result. Inhibitors and inducers of CYP3A4 and inhibitors of CYP2D6 are not allowed.
  • Subjects who have supine, sitting, or standing blood pressure, after resting for ≥ 3 minutes, higher than 130/80 mmHg or lower than 100/50 mmHg. The sponsor may allow exceptions if they are not deemed clinically significant.

Exclusion Criteria for Renally Impaired Subjects

  • Subjects that have undergone a renal transplant.
  • Renally impaired subjects may be taking medications which, in the opinion of the clinical investigator and sponsor, are believed to be therapeutic for the subjects (but do not affect OPC-34712 absorption, distribution, metabolism, or elimination). Inhibitors and inducers of CYP3A4 and inhibitors of CYP2D6 are not allowed.
  • Clinically significant abnormal findings in the serum chemistry, hematology, or urinalysis results obtained at Screening or Day -1, other than those associated with underlying renal conditions and other stable medical conditions consistent with the disease processes.
  • Subject requiring dialysis or expected to require dialysis within 45 days.
  • Subjects who have supine, sitting, or standing blood pressure, after resting for ≥ 3 minutes, higher than 160/95 mmHg or lower than 100/50 mmHg. The sponsor may allow exceptions if they are not deemed clinically significant.
  • Subjects with evidence of delirium.
  • Clinically relevant changes on such as any atrioventricular block, prolongation of the QRS complex over 120 msec (for both male and female subjects), or with a interval ≥ 450 msec.
  • Any subject who, in the opinion of the sponsor or the investigator, should not participate in the trial.
  • Consumption of alcohol and/or food and beverages containing methylxanthines, grapefruit, grapefruit juice, Seville oranges, or Seville orange juice within 72 hours prior to dosing.
  • Use of any drug known or suspected of inhibiting or stimulating hepatic drug metabolism enzymes within 30 days prior to Screening.
  • Exposure to any substances known to stimulate hepatic microsomal enzymes within 30 days prior to Screening through the end of the trial (eg, occupational exposure to pesticides, organic solvents).
  • History of serious mental disorders.
  • Major surgery of the digestive tract (excluding appendectomy).
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Active comparator
    Group 1

    subjects with normal renal function

    Drug: OPC-34712

  • Active comparator
    Group 2

    severely renally impaired subjects

    Drug: OPC-34712

Interventions

06

What researchers measure

Primary outcomes

  1. Unbound Area Under the Concentration (AUC) Time Curve Calculated to the Last Observable Concentration Brexpiprazole (AUCt,u).

    Blood samples were collected on Day 1 at Predose (within 15 minutes of dosing) and at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours Postdose or at Early Termination (ET). Unbound fraction of drug in plasma was calculated as 100% - mean percent of brexpiprazole bound to plasma protein for each participant.

    Time frame: Day 1 to Day 8

  2. Unbound Area Under AUC- Time Curve From Time Zero to Infinity (AUC∞,u).

    Blood samples were collected at Predose (within 15 minutes of dosing) and at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours or at ET. Unbound fraction of drug in plasma was calculated as 100% - mean percent of brexpiprazole bound to plasma protein for each participant.

    Time frame: Day 1 to Day 8

  3. Unbound Maximum (Peak) Plasma Concentration of Brexpiprazole (Cmax,u).

    Blood samples were collected at Predose (within 15 minutes of dosing) and at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours or at ET. Unbound fraction of drug in plasma was calculated as 100% - mean percent of brexpiprazole bound to plasma protein for each participant.

    Time frame: Day 1 to Day 8

Secondary outcomes

  1. AUC Time Curve of Brexpiprazole Metabolite (DM-3411) Calculated to the Last Observable Concentration at Time t (AUCt).

    Blood samples were collected at Predose (within 15 minutes of dosing) and at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours or at ET. The AUCt was estimated using the linear trapezoidal rule.

    Time frame: Day 1 to Day 8

  2. AUC Time Curve of Brexpiprazole From Time Zero to Infinity (AUC∞).

    Blood samples were collected at Predose (within 15 minutes of dosing) and at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours or at ET. The AUC∞ was estimated using the linear trapezoidal rule.

    Time frame: Day 1 to Day 8

  3. Maximum Plasma Concentration of Brexpiprazole Metabolite (DM-3411) (Cmax).

    Blood samples were collected at Predose (within 15 minutes of dosing) and at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours or at ET. Unbound fraction of drug in plasma was calculated as 100% - mean percent of brexpiprazole bound to plasma protein for each participant.

    Time frame: Day 1 to Day 8

  4. Time to Cmax of Brexiprazole Metabolite (DM-3411) (Tmax).

    Blood samples were collected at Predose (within 15 minutes of dosing) and at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours or at ET. Tmax is the time taken to reach highest measured concentration of the drug during the dosing interval.

    Time frame: Day 1 to Day 8

  5. Apparent Clearance From Plasma After Extravascular Administration of Brexpiprazole (CL/F).

    The value of CL/F was determined as Dose/AUC∞. Clearance of a drug was a measure of the rate at which a drug was metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) was influenced by the fraction of the dose absorbed. Clearance was estimated from population PK modeling. Drug clearance was a quantitative measure of the rate at which a drug substance was removed from the blood.

    Time frame: Day 1 to Day 8

  6. Unbound Fraction of Brexpiprazole in Plasma (fu).

    Blood samples were collected at Predose (within 15 minutes of dosing) and at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours or at ET. Unbound fraction of drug in plasma was calculated as 100% - mean percent of brexpiprazole bound to plasma protein for each participant.

    Time frame: Day 1 to Day 8

  7. Apparent Unbound Clearance From Plasma After Extravascular Administration of Brexpiprazole (CLu/F).

    Blood samples were collected at Predose (within 15 minutes of dosing) and at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours or at ET. Unbound fraction of drug in plasma was calculated as 100% - mean percent of brexpiprazole bound to plasma protein for each participant.

    Time frame: Day 1 to Day 8

  8. Terminal-phase Elimination Half-life of Brexpiprazole (t1/2,z).

    Blood samples were collected at Predose (within 15 minutes of dosing) and at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours or at ET. Unbound fraction of drug in plasma was calculated as 100% - mean percent of brexpiprazole bound to plasma protein for each participant.

    Time frame: Day 1 to Day 8

  9. Renal Clearance (CLr) of Brexipiprazole Metabolite (DM-3411).

    Urine samples were collected at Predose at intervals of 0 to 24, 24 to 48, 48 to 72, 72 to 96, 96 to 120, 120 to 144, and 144 to 168 hours postdose. Unbound fraction of drug in plasma was calculated as 100% - mean percent of brexpiprazole bound to plasma protein for each participant.

    Time frame: Day 1 to Day 8

  10. Fraction of the Systemically Available Brexpiprazole Metabolite (DM-3411) Excreted Into the Urine (fe,u).

    Urine samples were collected at Predose and at intervals of 0 to 24, 24 to 48, 48 to 72, 72 to 96, 96 to 120, 120 to 144, and 144 to 168 hours postdose. Unbound fraction of drug in plasma was calculated as 100% - mean percent of brexpiprazole bound to plasma protein for each participant.

    Time frame: Day 1 to Day 8

  11. The Abnormalities Found in Vital Signs, ECGs, and Clinical Laboratory Tests Are Reported as AEs Upon Study Physicians Discretion.

    An adverse event (AE) was an exacerbation of an existing problem or any new problem, experienced by a participant when enrolled in a trial, whether or not it was considered drug related by the study physician.

    Time frame: AEs were recorded from Screening (ICF was signed) to Follow-up 31 (+ 2) days.

07

Results

Posted Oct 29, 2015

Participant flow

The trial was an open-label, multicenter, parallel-arm, single-dose trial in two groups: 1 group of participants with normal renal function and 1 group of severely renally impaired participants.

Participant flow — Overall Study
MilestoneNormalRenally Impaired
Started910
Completed910
Not completed00

Outcome measures

PrimaryUnbound Area Under the Concentration (AUC) Time Curve Calculated to the Last Observable Concentration Brexpiprazole (AUCt,u).

Blood samples were collected on Day 1 at Predose (within 15 minutes of dosing) and at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours Postdose or at Early Termination (ET). Unbound fraction of drug in plasma was calculated as 100% - mean percent of brexpiprazole bound to plasma protein for each participant.

Time frame:
Day 1 to Day 8
Reported as:
Mean · nanograms*hours/mL (ng*h/mL)
Unbound Area Under the Concentration (AUC) Time Curve Calculated to the Last Observable Concentration Brexpiprazole (AUCt,u).
nanograms*hours/mL (ng*h/mL)NormalRenally Impaired
Unbound Area Under the Concentration (AUC) Time Curve Calculated to the Last Observable Concentration Brexpiprazole (AUCt,u).8.17 ± 1.3713.3 ± 6.26
PrimaryUnbound Area Under AUC- Time Curve From Time Zero to Infinity (AUC∞,u).

Blood samples were collected at Predose (within 15 minutes of dosing) and at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours or at ET. Unbound fraction of drug in plasma was calculated as 100% - mean percent of brexpiprazole bound to plasma protein for each participant.

Time frame:
Day 1 to Day 8
Reported as:
Mean · ng*h/mL
Unbound Area Under AUC- Time Curve From Time Zero to Infinity (AUC∞,u).
ng*h/mLNormalRenally Impaired
Unbound Area Under AUC- Time Curve From Time Zero to Infinity (AUC∞,u).9.58 ± 2.2618.0 ± 8.72
PrimaryUnbound Maximum (Peak) Plasma Concentration of Brexpiprazole (Cmax,u).

Blood samples were collected at Predose (within 15 minutes of dosing) and at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours or at ET. Unbound fraction of drug in plasma was calculated as 100% - mean percent of brexpiprazole bound to plasma protein for each participant.

Time frame:
Day 1 to Day 8
Reported as:
Mean · ng/mL
Unbound Maximum (Peak) Plasma Concentration of Brexpiprazole (Cmax,u).
ng/mLNormalRenally Impaired
Unbound Maximum (Peak) Plasma Concentration of Brexpiprazole (Cmax,u).0.195 ± 0.06620.198 ± 0.0702
SecondaryAUC Time Curve of Brexpiprazole Metabolite (DM-3411) Calculated to the Last Observable Concentration at Time t (AUCt).

Blood samples were collected at Predose (within 15 minutes of dosing) and at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours or at ET. The AUCt was estimated using the linear trapezoidal rule.

Time frame:
Day 1 to Day 8
Reported as:
Mean · ng*h/mL
AUC Time Curve of Brexpiprazole Metabolite (DM-3411) Calculated to the Last Observable Concentration at Time t (AUCt).
ng*h/mLNormalRenally Impaired
AUC Time Curve of Brexpiprazole Metabolite (DM-3411) Calculated to the Last Observable Concentration at Time t (AUCt).1410 ± 4232080 ± 1230
SecondaryAUC Time Curve of Brexpiprazole From Time Zero to Infinity (AUC∞).

Blood samples were collected at Predose (within 15 minutes of dosing) and at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours or at ET. The AUC∞ was estimated using the linear trapezoidal rule.

Time frame:
Day 1 to Day 8
Reported as:
Mean · ng*h/mL
AUC Time Curve of Brexpiprazole From Time Zero to Infinity (AUC∞).
ng*h/mLNormalRenally Impaired
AUC Time Curve of Brexpiprazole From Time Zero to Infinity (AUC∞).2050 ± 5103800 ± 1970
SecondaryMaximum Plasma Concentration of Brexpiprazole Metabolite (DM-3411) (Cmax).

Blood samples were collected at Predose (within 15 minutes of dosing) and at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours or at ET. Unbound fraction of drug in plasma was calculated as 100% - mean percent of brexpiprazole bound to plasma protein for each participant.

Time frame:
Day 1 to Day 8
Reported as:
Mean · ng/mL
Maximum Plasma Concentration of Brexpiprazole Metabolite (DM-3411) (Cmax).
ng/mLNormalRenally Impaired
Maximum Plasma Concentration of Brexpiprazole Metabolite (DM-3411) (Cmax).18.2 ± 6.2419.8 ± 12.3
SecondaryTime to Cmax of Brexiprazole Metabolite (DM-3411) (Tmax).

Blood samples were collected at Predose (within 15 minutes of dosing) and at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours or at ET. Tmax is the time taken to reach highest measured concentration of the drug during the dosing interval.

Time frame:
Day 1 to Day 8
Reported as:
Median · h
Time to Cmax of Brexiprazole Metabolite (DM-3411) (Tmax).
hNormalRenally Impaired
Time to Cmax of Brexiprazole Metabolite (DM-3411) (Tmax).12.0 ± 1.00-8.0030.0 ± 2.00-8.00
SecondaryApparent Clearance From Plasma After Extravascular Administration of Brexpiprazole (CL/F).

The value of CL/F was determined as Dose/AUC∞. Clearance of a drug was a measure of the rate at which a drug was metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) was influenced by the fraction of the dose absorbed. Clearance was estimated from population PK modeling. Drug clearance was a quantitative measure of the rate at which a drug substance was removed from the blood.

Time frame:
Day 1 to Day 8
Reported as:
Mean · mL/h/kg
Apparent Clearance From Plasma After Extravascular Administration of Brexpiprazole (CL/F).
mL/h/kgNormalRenally Impaired
Apparent Clearance From Plasma After Extravascular Administration of Brexpiprazole (CL/F).23.0 ± 8.0514.2 ± 6.46
SecondaryUnbound Fraction of Brexpiprazole in Plasma (fu).

Blood samples were collected at Predose (within 15 minutes of dosing) and at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours or at ET. Unbound fraction of drug in plasma was calculated as 100% - mean percent of brexpiprazole bound to plasma protein for each participant.

Time frame:
Day 1 to Day 8
Reported as:
Mean · % of unbound brexpiprazole in plasma
Unbound Fraction of Brexpiprazole in Plasma (fu).
% of unbound brexpiprazole in plasmaNormalRenally Impaired
Unbound Fraction of Brexpiprazole in Plasma (fu).0.476 ± 0.05250.492 ± 0.0346
SecondaryApparent Unbound Clearance From Plasma After Extravascular Administration of Brexpiprazole (CLu/F).

Blood samples were collected at Predose (within 15 minutes of dosing) and at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours or at ET. Unbound fraction of drug in plasma was calculated as 100% - mean percent of brexpiprazole bound to plasma protein for each participant.

Time frame:
Day 1 to Day 8
Reported as:
Mean · mL/h/kg
Apparent Unbound Clearance From Plasma After Extravascular Administration of Brexpiprazole (CLu/F).
mL/h/kgNormalRenally Impaired
Apparent Unbound Clearance From Plasma After Extravascular Administration of Brexpiprazole (CLu/F).0.110 ± 0.04930.0686 ± 0.0336
SecondaryTerminal-phase Elimination Half-life of Brexpiprazole (t1/2,z).

Blood samples were collected at Predose (within 15 minutes of dosing) and at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours or at ET. Unbound fraction of drug in plasma was calculated as 100% - mean percent of brexpiprazole bound to plasma protein for each participant.

Time frame:
Day 1 to Day 8
Reported as:
Mean · h
Terminal-phase Elimination Half-life of Brexpiprazole (t1/2,z).
hNormalRenally Impaired
Terminal-phase Elimination Half-life of Brexpiprazole (t1/2,z).71.7 ± 23.887.4 ± 28.9
SecondaryRenal Clearance (CLr) of Brexipiprazole Metabolite (DM-3411).

Urine samples were collected at Predose at intervals of 0 to 24, 24 to 48, 48 to 72, 72 to 96, 96 to 120, 120 to 144, and 144 to 168 hours postdose. Unbound fraction of drug in plasma was calculated as 100% - mean percent of brexpiprazole bound to plasma protein for each participant.

Time frame:
Day 1 to Day 8
Reported as:
Mean · mL/h/kg
Renal Clearance (CLr) of Brexipiprazole Metabolite (DM-3411).
mL/h/kgNormalRenally Impaired
Renal Clearance (CLr) of Brexipiprazole Metabolite (DM-3411).1.38 ± 0.8830.683 ± 0.471
SecondaryFraction of the Systemically Available Brexpiprazole Metabolite (DM-3411) Excreted Into the Urine (fe,u).

Urine samples were collected at Predose and at intervals of 0 to 24, 24 to 48, 48 to 72, 72 to 96, 96 to 120, 120 to 144, and 144 to 168 hours postdose. Unbound fraction of drug in plasma was calculated as 100% - mean percent of brexpiprazole bound to plasma protein for each participant.

Time frame:
Day 1 to Day 8
Reported as:
Mean · % of unbound brexpiprazole in urine.
Fraction of the Systemically Available Brexpiprazole Metabolite (DM-3411) Excreted Into the Urine (fe,u).
% of unbound brexpiprazole in urine.NormalRenally Impaired
Fraction of the Systemically Available Brexpiprazole Metabolite (DM-3411) Excreted Into the Urine (fe,u).3.91 ± 1.662.55 ± 1.19
SecondaryThe Abnormalities Found in Vital Signs, ECGs, and Clinical Laboratory Tests Are Reported as AEs Upon Study Physicians Discretion.

An adverse event (AE) was an exacerbation of an existing problem or any new problem, experienced by a participant when enrolled in a trial, whether or not it was considered drug related by the study physician.

Time frame:
AEs were recorded from Screening (ICF was signed) to Follow-up 31 (+ 2) days.
Reported as:
Number · participants
The Abnormalities Found in Vital Signs, ECGs, and Clinical Laboratory Tests Are Reported as AEs Upon Study Physicians Discretion.
participantsNormalRenally Impaired
Participants with adverse events35
Participants with TEAEs35
Participants with severe TEAEs01

Adverse events

Collected over AEs were recorded from Screening (ICF was signed) to Follow-up 31 (+ 2) days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brexpiprazole 3mg—0/19 (0%)8/19 (42.1%)
Most frequent other events
Most frequent other events
EventBrexpiprazole 3mg
SomnolenceNervous system disorders3/19
HeadacheNervous system disorders2/19
Orthostatic hypotensionVascular disorders2/19
ConstipationGastrointestinal disorders1/19
DizzinessNervous system disorders1/19
HypotensionVascular disorders1/19
NauseaGastrointestinal disorders1/19
Upper respiratory tract infectionInfections and infestations1/19

Baseline characteristics

Age, Continuous
Age, Continuous(Years)NormalRenally ImpairedTotal
Mean58.8 ± 10.162.9 ± 12.260.9 ± 11.1
Sex: Female, Male
Sex: Female, Male(Participants)NormalRenally ImpairedTotal
Female336
Male6713
08

Study locations

2 sites
  • Otsuka Investigational Site
    Miami, Florida 33014, United States
  • Otsuka Investigational Site
    Minneapolis, Minnesota 55404, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2011, a primary completion of Dec 2011 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2015, 3 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2011
First posted
Feb 3, 2011
Start
Jan 2011
Primary completionActual
Dec 2011
CompletionActual
Jan 2012
Results first posted
Oct 29, 2015
Last update
Oct 29, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 29, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01289080
Responsible party
Sponsor
First posted
Feb 3, 2011
Start date
Jan 2011
Primary completion
Dec 2011
Completion
Jan 2012
Results posted
Oct 29, 2015
Last update
Oct 29, 2015

Study contacts

Aleksandar Skuban
study director · Otsuka Pharmaceutical Development & Commercialization, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brexpiprazole

Start the discussion